Cizzle Biotechnology Holdings plc (LON:CIZ) Executive Chairman Allan Syms joins DirectorsTalk Interviews to discuss a full commercial development and royalty agreement to develop and market Cizzle Biotechnologies early lung cancer diagnostic tests in China.
Allan provides us with more information around the deal, tells us about the diagnostic technology and what it does, explains who its partners are in China and how this arrangement in China will work from a financial point of view and potentially generate future revenues for the company.
Cizzle Biotechnology is a UK based developer of a blood test for the early detection of a majority of different forms of lung cancer.
